SPONSOR
Haihe Biopharma Co., Ltd.
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 2
Conditions studied: FL LymphomaEpithelioid SarcomaPeripheral T Cell LymphomaAdvanced Solid TumorPIK3CA-Related Overgrowth Spectrum (PROS)PIK3CA-related Vascular Malformations (PRVM)
NCT04390737 Phase 1, Phase 2
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
FL Lymphoma
NCT06975618 Phase 1, Phase 2
Recruiting
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)
PIK3CA-Related Overgrowth Spectrum (PROS)